Acute Colonic Pseudoobstruction (Ogilvie Syndrome) - A Severe Complication in the Evolution of the Hospitalized or Institutionalized Patients

Bogdan Socea¹, Simona Bobic², Dan Nicolae Păduraru¹, Alexandru C. Carâp*¹, Anca A. Nica¹, Alexandru C. Smaranda¹, Vladimir Ciobotaru¹, Cristiana Bogaciu², Ion Pâun¹, Ovidiu Gabriel Bratu³, Cristinel D. Badiu¹, Dragoș Predescu¹, Vlad Denis Constantin¹

¹Carol Davila University of Medicine and Pharmacy, Surgery Department, Sf. Pantelimon Emergency Clinical Hospital, Bucharest, Romania
²Surgery Department, Sf. Pantelimon Emergency Clinical Hospital, Bucharest, Romania
³University of Medicine and Pharmacy of Craiova, CF Craiova Clinical Hospital, Surgery Department, Craiova, Romania
⁴Carol Davila University of Medicine and Pharmacy, Urology Department, Central Clinical Military Hospital, Bucharest, Romania
⁵Carol Davila University of Medicine and Pharmacy, Surgery Department, Bagdasar-Arseni Emergency Clinical Hospital, Bucharest, Romania
⁶Carol Davila University of Medicine and Pharmacy, Surgery Department, Sf. Maria Clinical Hospital, Bucharest, Romania

*Corresponding author:
Alexandru C. Carâp, MD
Carol Davila University of Medicine and Pharmacy, Surgery Department, Sf. Pantelimon Emergency Clinical Hospital, Bucharest, Romania
E-mail: alexandru.carap@umfcd.ro

Rezumat

Pseudo-obstrucția intestinală acută (sindromul Ogilvie) – o complicație severă în evoluția pacienților spitalizați sau instituționalizați


Material și metodă: Pe lângă experiența noastră, a fost elaborat un studiu al literaturii recente de specialitate în scopul evaluării incidenței, etiologiei, tabloului clinic și diagnosticului pseudo-obstrucției intestinale acute.

Rezultate și Concluzii: Scopul prezentului studiu este de a stabili algoritmul terapeutic optim pentru pacienții critici cu risc înalt de
complicații de tipul pseudo-obstrucției intestinale acute, pe baza datelor publicate in literatura de specialitate.

Cuvinte cheie: Ogilvie, pseudo-obstrucție, colon

Abstract

Introduction: Ogilvie syndrome, or acute colonic pseudo-obstruction (ACPO), represents a pathological entity, potentially with a severe outcome, due to the acute important dilation of the large bowel, in the absence of a mechanical luminal obstruction. Usually, it occurs in patients admitted in intensive care unit, that associate severe surgical or medical pathologies. The mechanism of the ACPO has not been completely explained, but it is assumed that the motor function of the colon may be affected, as a result of autonomic regulation disturbance. Early diagnosis and treatment help reduce the risk of severe outcome, such as ischemia or perforation.

In addition to our experience, a literature search was elaborated in order to evaluate the incidence, the etiology, the clinical presentation and the diagnosis of the ACPO. The present study may be of help in the process of guiding the optimal management of a critically ill patient is at high risk of developing colonic pseudo-obstruction.

Key words: Ogilvie, pseudo-obstruction, colon

Introduction

Acute colonic pseudo-obstruction (ACPO) was first described in 1948 by Sir William Heneage Ogilvie (1), as an important dilation of the large bowel, having non-specific symptoms. It presents clinical and radiological signs of acute occlusion without an identifiable obstacle (2). Several risk factors have been described in the etiology of the ACPO: neurological diseases, politrauma, sepsis, viral infections like SARS-CoV2, recent non-abdominal surgery (orthopedics, neurosurgery). The non-specificity of the clinical presentation in Ogilvie syndrome may lead to a delay in the diagnosis. An important step in the differential diagnosis process is to rule out the mechanical and other toxic causes of colonic paresis. The goal of the therapeutic management patients with ACPO is to evacuate the colon and lower the intraluminal pressure, thus minimizing risks of consecutive ischemia/necrosis and even perforation, complications known to associate high mortality rates (3). Supportive therapy, neostigmine administration in case of failure of medical treatment and colonoscopy for decompression represent the optimal first therapeutic steps, the surgical intervention being indicated only in those cases with peritonitis or perforation. Taking into consideration the relatively high incidence of the ACPO within the hospitalized or institutionalized cases, as shown by the results of the present study, it is imperative to implement early diagnostic and therapeutic protocols. The aim of the study is to evaluate the incidence, the risk factors and the optimal diagnostic-therapeutic algorithm for Ogilvie syndrome, through a search of the recent international literature on the matter.

Material and Method

A systematic search of the Web of Science and Ovid HTTPS databases was performed from August 2009 to August 2019, using the search terms “Ogilvie’s syndrome”, “pseudoobstruction”, and “pseudo obstruction”. PubMed and Google Scholar were also searched using free text entries. The resulted articles were
selected by title and abstract for inclusion, with subsequent acquisition of full texts. The reference lists of included papers were manually searched, and a hand search of the scientific literature was performed to identify additional relevant publications. Only the articles using English language were included in the present study. There were no exclusion limits by study design: both primary research and review articles were eligible. Full-text articles were evaluated for evidence addressing the definition, epidemiology, risk factors, aetiology and pathogenesis of ACPO. A narrative synthesis of the identified evidence was undertaken.

RESULTS

Definition of ACPO

ACPO is characterized by acute colonic dilatation in the absence of a mechanical or toxic cause of obstruction. Many overlapping terms have been used in order to describe ACPO, since its original description in 1948 by Sir William Heneage Ogilvie, thus demonstrating the uncertainty regarding its etiology (large intestine colic, Ogilvie's syndrome, pseudo-megacolon, adynamic ileus, paralytic ileus, functional obstruction of the intestinal tract, idiopathic large bowel obstruction, colonic ileus, etc.). The term “intestinal pseudo-obstruction” was first proposed by Dudley in 1958, with “ACPO” not appearing for another twenty years (1). Use of “Ogilvie’s syndrome” has been discouraged due to ambiguity regarding its meaning, though considerable heterogeneity in terminology still exists in recent literature (1).

Epidemiology of the ACPO

The exact prevalence of ACPO is not well known, the highest prevalence being observed in late middle age (the sixth decade). Men are more affected compared to women (60%) (4). It appears more frequent in admitted patients from normal wards or intensive care units, most of them having associated other medical conditions. It is observed in approximately 1% of patients after complex orthopedic interventions (like joint prosthesis, spinal interventions) (5). ACPO is an affection with poor prognosis, having important clinical and social consequences, increasing costs and time of hospitalization. Recent studies (6) have shown a high overall mortality rate of approximate 30% and increased even towards 50% when developing ischemia or perforation (3,7-9), that are directly correlated to associated illnesses, late diagnosis and inadequate treatment.

Physiopathology

The physiopathology of the ACPO is not completely understood, but it may be a result of an imbalanced regulation of the parasympathetic innervation of the colon, that increases contractility, versus the sympathetic one, that inhibits motility (10). Thus, a dysfunction of the autonomic regulation, secondary to multiple factors, may determine an augmentation of parasympathetic control or a sympathetic stimulation, resulting in a colic paresis (3).

Several metabolic syndromes (electrolyte imbalance, hepatic failure, renal failure), pharmacologic causes (anti-Parkinson drugs, anticholinergics, calcium channel blockers psychotropic drugs, epidural analgetics), traumatic factors (complex surgical interventions, infections), cardiac/neurological diseases, sepsis, viral infections (like SARS-CoV-2) are implicated in the autonomic adjustment of colic mobility, leading to pseudo-obstruction (3,10). A retrospective study of 400 patients having Ogilvie syndrome, showed that the most frequent associated conditions were surgical interventions, non-operative trauma, infections, heart diseases (3), with Cesarean section and hip surgery being the most common surgical procedures.

Diagnosis

Abdominal distension represents a constant clinical finding, present in almost all patients with ACPO (3). Abdominal meteorism usually
appears in the first 3-7 days, but can develop even more rapid, in the first 24-48 hours. Other frequently encountered findings are represented by nausea/vomiting (60% cases), high temperature, constipation or, paradoxically, diarrhea. Dyspnea may be present in these patients, as a consequence of the important distention of the abdomen (1,3,4). The clinical examination may reveal a tympanic abdomen on percussion, high-pitched 'tinkling' or reduced/absent bowel sounds on auscultation. It has been observed that it is difficult to distinguish patients with bowel ischemia and perforation from those presenting only important, but uncomplicated abdominal distension. Peritoneal signs and fever can make the difference (10). Thus, the suspicion for this syndrome must remain high in all cases of colonic distension, and the use of diagnostic tests is essential for early detection. For operated patients, signs and symptoms usually occur in the first 5 postoperative days.

The diagnostic of Ogilvie syndrome is often clinically suggested. Its confirmation comes from the plain abdominal radiography, that shows dilatations of the colon and small bowel and sometimes even air fluid levels. The most dilated areas are usually located at the level of caecum and the ascending colon, commonly till the splenic flexure or the descending colon. This pathological distribution of dilatations seems to be related to different territories innervated by the parasympathetic autonomic system from different origins. The presence of pneumoperitoneum and pneumatosis must be assessed.

The main differential diagnostic of Ogilvie syndrome should be made with bowel occlusion of mechanical cause (11,12). Other conditions that should be excluded, are: paraneoplastic syndromes (13), inflammatory bowel diseases (14,15), Clostridium difficile or other colonic infections with toxic megacolon (16), retroperitoneal tumors (17). Water-soluble contrast enema radiography (96% sensitivity and 98% specificity (18)), or computed tomography (CT with both sensitivity and specificity of 91% (19)) may differentiate the mechanical obstruction from pseudo-obstruction. On CT sections, we can accurately measure the diameter of the colon and a fare evaluation of the inflammation and mucosal state can be done by wall measurements. Wall thickening, submucosal oedema and intramural gas are relevant for ischaemic changes of the mucosa with/without advancing necrosis. The endoscopic evaluation of the colon may split Ogilvie syndrome from obstruction causes. Although, colonoscopy is not the best method for these causes because of perforative risks.

**Therapeutical Management**

The essential steps in the management of ACPO are represented by early recognition and diagnosis, excluding mechanical obstruction or any other causes of ileus, evaluation of signs that could early detect ischemia or perforation, that urgently impose a surgical attitude.

Therapeutic management is oriented by colonic distention and the vascularisation of the bowel. Fig. 1 shows a proposed plan for the therapeutic management of Ogilvie syndrome, according to the American Society of Colon and Rectal Surgeons (ASCRS) (10).

Spontaneous colonic perforation appears in about 3% patients with ACPO (9), increasing in case of a cecal diameter greater than 12 cm (other studies indicate a 14 cm diameter) and a duration of distension of more than 6 days. There are no clear evidences regarding the degree of cecal distentions and its duration. Any cecal distension, greater than 10cm, that last for more than 72 hours is considered to have high risks of ischemia and perforation (Fig. 2).

The recommended management for Ogilvie syndrome in non-complicated cases, and no imminence of cecal perforation remains conservative therapy: hydro-electrolyte rebalancing (especially treatment of hypokalemia and hypomagnesaemia), fluid resuscitation, avoidance or minimisation of drugs administration that delay intestinal movements (anticholinergic drugs, opiates, calcium ionic channels blockers),
Acute Colonic Pseudoobstruction (Ogilvie Syndrome) - A Severe Complication in the Evolution of the Hospitalized or Institutionalized Patients

Acute Colonic Pseudoobstruction (ACPO) is a severe complication often seen in hospitalized or institutionalized patients, characterized by colonic dilation without mechanical or toxic obstruction. The treatment of such patients should include bowel rest, ambulation, prone positioning to facilitate gas elimination, and naso-gastric tube insertion or rectal gas tube insertion to facilitate stomach and colon decompression. Avoiding oral osmotic substances or irritant laxatives is recommended, as they could exacerbate the condition by promoting gas production and propagation into an already dilated colon, leading to worsening colonic dilation.

Detection of ischemia or perforation necessitates regular clinical examinations and abdominal radiography without contrast. Clinical findings indicative of bowel ischemia include pain, abdominal tenderness or guarding, sepsis signs, fever, and elevated C reactive protein and white blood count. If no clinical or paraclinical signs of colon ischemia, perforation, or imminent perforation are present, conservative measures are recommended for 48-72 hours. This treatment typically resolves symptoms in approximately 70%-90% of cases of ACPO.

If there are no signs of ischemia or perforation and no response to conservative management, drug treatment with Neostigmine intravenously administered should be considered, as it acts by inhibiting acetylcholinesterase. This approach should be initiated as a golden standard initial therapy. Neostigmine is known to facilitate bowel mobility and reduce colonic dilation by reversing the effects of acetylcholinesterase inhibition.

The mechanism of action for neostigmine involves its ability to block the enzyme acetylcholinesterase, preventing the breakdown of acetylcholine, thereby increasing the availability of acetylcholine in the muscles and nerves. This increased availability of acetylcholine can lead to enhanced muscle contractions and improved bowel motility.

Figure 1. Therapeutical algorithm for ACPO, according to the American Society of Colon and Rectal Surgeons (ASCRS)
down of acetylcholine, the drug increases the level of acetylcholine in the parasympathetic synapses that will bind to receptors. The colonic effect of acetylcholine translates into the stimulation of peristalsis. Through this effect, neostigmine has been shown to reduce large bowel dilation in approximately 90% of cases of ACPO, as demonstrated in 3 Placebo-controlled, prospective randomized trials (20).

Administration of 2 mg of neostigmine, intravenously in 3-5 minutes, results in a rapid clinical response - on average in 4 minutes (between 3 and 30 minutes) -, consisting of resumption of peristalsis and emptying of the colon. In patients who do not respond to the first dose, another one may be given after an interval that ensures the metabolism of first neostigmine dose (above the half-life time, that is 80 minutes). This second dose is effective in 40% to 100% of them (21).

The use of neostigmine is associated with several important side effects, such as bronchospasm, hypotension, bradycardia and even syncope. Therefore, the administration is done only under strict monitoring of blood pressure, pulse and electrocardiographic line. Cases of severe bradycardia usually respond to atropine. The risks are higher in case of bolus administration of a high or complete dose. Therefore, it is recommended that the initial dose should not exceed 1 mg, or that the administration should be slow (continuous intravenous perfusion of 0,4 - 0,8 mg neostigmine per hour, over 24h) (21). Absolute contraindications are represented by the appearance of colonic perforation, pregnancy, cardiac arrhythmias, bronchospasm, while relative contraindications are: recent bowel perforation, perforated peptic ulcer, cardiac ischemia, beta-blockers consume, chronic obstructive pulmonary disease, asthma, renal failure (creatinine above 3 mg/dl). For bradycardic patients, patients with renal failure, asthma or chronic obstructive pulmonary disease, recent myocardial infarctisation, neostigmine can only be administered with special precautions.

Colonoscopic decompression is indicated in extreme cases, with important dilatation of the large bowel, that do not respond to neostigmine and conservative treatment, or when there is a contraindication for the administration of neostigmine (Fig. 3). Recent studies have demonstrated an efficiency of 61% to 95% in initial colon decompression, and of 70% to 90% in case of sustained decompression (3, 20). Most of the times, the colonoscopic decompression procedure needs to be repeated periodically as many times as necessary, as well as the installation of the intraanal gas decompression tube.

Surgical therapy is recommended only for complicated disease, with colic ischemia and perforation or for the patients that not respond to neostigmine and colonoscopic decompression. The results of the recently published literature showed a 10% rate of persistent colon dilation refractory to non-operative measures (10, 22).

The main disadvantages of the surgical management are represented by the high morbidity and mortality rates, possibly in relation with severe co-morbidities.
Discussion

The present article highlights the fact that the mechanisms involved in the physiopathology of the ACPO still remain uncertain. There are limited physiological evidence from patients with ACPO and the lack of proper animal models has required extrapolation of data from other disease studies. Multiple risk factors and associated conditions have been identified, thus supporting a multifactorial hypothesis in the physiopathology of the ACPO. It has been shown by multiple recent studies that the autonomic imbalance of the colon plays a key role in the development of the Ogilvie syndrome, an idea that can be sustained by the sudden transition point from distended to normal colon in ACPO usually occurring at the splenic flexure, this anatomic site corresponding to the change in autonomic innervation of the mid-gut and hind-gut. However, the precise mechanism involved in the autonomic function leading to ACPO remains unclear.

ACPO still represents a pathological entity difficult to investigate due to its acute and sporadic nature and heterogeneity. The large number of case reports, in contrast with the limited number of case series or cohort studies identified in the literature, is testament to the large number of illnesses associated with this condition and to the absence of a clear definition of ACPO. It can be deduced that there is no categorical clinical description of the ACPO because there is limited evidence investigating the mechanisms underlying this condition.

A number of areas for further study have been identified, that include the development of an animal model of ACPO, histological examination of resected specimens, and rigorous investigation of the impact of preventative or therapeutic strategies on colonic function.

It is hoped that an improved understanding of the pathophysiology of ACPO will lead to the development of targeted strategies for its prevention and treatment.

Conclusions

• Ogilvie’s syndrome represents an abdominal distension syndrome, without any evidence of mechanical occlusion of the lumen.
• Diagnosis is established by plain abdominal radiography and computed tomography scan.
• Early and adequate treatment is a key factor in the evolution of the patients with ACPO that allows a lowered risk of complications.
• The initial recommended treatment is conservative: digestive rest, correction of hydroelectrolytic disorders and cessation of medication that may aggravate ileus.
• If no improvement is observed in the first 24-48 hours of conservative management, Neostigmine administration should be initiated, in the absence of contraindications.
• Endoscopic decompression is reserved only for those patients that do not respond to neostigmine.
• All cases with peritoneal irritation produced by a colonic perforation should required urgent surgical intervention.
• Other areas for future pathophysiological investigation include the development of an animal model of ACPO, histological examination of resected specimens, and rigorous investigation of the impact of preventative or therapeutic strategies on colonic function.
• It is also clear that a categorical clinical definition of ACPO is needed to standardize research, and improve the quality of published evidence.

Author’s Contributions

All authors equally contributed to this manuscript.

Conflict of Interest

The authors declare no conflicts of interests.